The Myogenes Clozapine Test - Myogenes

The Myogenes Clozapine Test

Developed  in collaboration with Prof. David Taylor, the clozapine genetic test is for use in the treatment of schizophrenia.

An easy to administer simple saliva test that looks at evidence based genes associated with a patient’s response to clozapine.

£480.00 inc VAT  |   Free UK Shipping

The Myogenes Clozapine Test

Developed  in collaboration with Prof. David Taylor, the clozapine genetic test is for use in the treatment of schizophrenia.

An easy to administer simple saliva test that looks at evidence based genes associated with a patient’s response to clozapine.

£480.00 inc VAT

Free UK Shipping

Book a free consultation today

Want to find out how our Clozapine Test can help you? Fill out the form below and one of our advisors will contact you to answer any questions.

Genetic health gene test

This test is for…

All people for whom clozapine is being considered plus:

  • People with schizophrenia.
  • Current clozapine patients who cannot achieve a therapeutic level despite high dose clozapine.
  • Inadequate response to treatment despite the sequential use of adequate doses of at least 2 different antipsychotic drugs: at least 1 of the drugs should be a non-clozapine second-generation antipsychotic.

In addition, patients already receiving clozapine:

  • Patients with only a partial treatment response.
  • Patients where neutrophil counts necessitate interruption of treatment.
  • Patients with possible benign ethnic neutropenia but their status is uncertain.

This test is for…

All people for whom clozapine is being considered plus:

  • Current clozapine patients whose BEN status is unknown.
  • Current clozapine patients who cannot achieve a therapeutic level despite high dose clozapine.
  • Inadequate response to treatment despite the sequential use of adequate doses of at least 2 different antipsychotic drugs: at least 1 of the drugs should be a non-clozapine second-generation antipsychotic

In addition, patients already receiving clozapine:

  • Patients with only a partial treatment response
  • Patients where neutrophil counts necessitate interruption of treatment
  • Patients with possible benign ethnic neutropenia but their status is uncertain

There are 24 million people in the world with treatment resistant schizophrenia (TRS)

Clozapine is the only effective treatment for TRS but is massively underused due to risk of adverse reactions.

The Myogenes Clozapine Test can minimise these risks, free up hospital beds, and save the NHS billions of pounds.

There are 24 million people in the world with treatment resistant schizophrenia (TRS)

Clozapine is the only effective treatment for TRS but is massively underused due to risk of adverse reactions.

The Myogenes Clozapine Test can minimise these risks, free up hospital beds, and save the NHS billions of pounds.

NICE Guidelines:

Adults with schizophrenia not responding to at least 2 antipsychotics should be offered clozapine.

However, clozapine is grossly underused whilst being the ONLY approved  treatment for treatment-resistant schizophrenia.

NICE Guidelines:

Adults with schizophrenia not responding to at least 2 antipsychotics should be offered clozapine.

However, clozapine is grossly underused whilst being the ONLY approved  treatment for treatment-resistant schizophrenia.

Ethnic minority groups are less likely to receive clozapine

This is owing to benign ethnic neutropenia (BEN), prevalent in ethnic minority groups.

If you belong to an ethnic minority group, you are less likely to receive clozapine resulting in higher hospitalisation and mortality.

Hospital admissions for TRS will cost the NHS in excess of £5 billion over the next 3 years

Acute hospital beds are being unnecessarily occupied at an astronomical cost to the NHS.

The Myogenes Business Impact Report (BIM) produced by CorEvitas, part of Thermo Fisher in conjunction with Health Innovation East projects that The Clozapine Test can save the NHS an estimated £1.8 billion over 3 years whilst drastically reducing self-harm incidents and hospital admissions.

Fill out the form below to receive a copy of the report.

Hospital admissions for TRS will cost the NHS in excess of £5 billion over the next 3 years

Acute hospital beds are being unnecessarily occupied at an astronomical cost to the NHS.

The Myogenes Business Impact Report (BIM) produced by CorEvitas, part of Thermo Fisher in conjunction with Health Innovation East projects that The Clozapine Test can save the NHS over £1.8 billion over 3 years whilst drastically reducing self-harm incidents and hospital admissions.

Fill out the form below to receive a copy of the report.

HOW TO GET A TEST

Contact us now to arrange your test

Office hours are:
9:00am – 5:30pm
Monday – Friday

We will call you back
within these hours

Office hours are:
9:00am – 5:30pm
Monday – Friday

We look forward to hearing from you soon